Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
109 Cards in this Set
- Front
- Back
what is a healthy body weight? normal, overweight range, morbid obesity
|
defined by BMI- normal is 18.5-24.9
overweight is 25-29.9 morbid obesity is > 40 |
|
disease risk and central obesity
|
central obesity is higher risk of disease even if 2 people have same BMI
|
|
excessive weight circumference range in men vs. women
abdominal adiposity as predictor of risk (what type of factor) |
Abdominal adiposity is BAD
Independent predictor of risk Men >40 inch Women >35 inch |
|
how to measure waist circumference
|
measure right above iliac crest (hip bone) and measure horizontally
|
|
% of americans obese
% overweight + % of children obese |
33% of american pop is obese
70% overweight+ wtf 17% of age 2-19 obese |
|
metabolic changes that occur when you become obese: duration
|
FOREVA
|
|
why the rapid change in obesity rates over the last 30 years? (3)
can't be explained by what? |
ENVIRONMENT!! “Obesogenic” environment
this means...Less exercise/activity More “unhealthy” diets cannot be explained by genetics because 30 years is too quick for evolution |
|
5 major consequences of obesity that put ppl at risk for serious health issues
3 other consequences |
Major risk for serious health consequences
Hypertension Dyslipidemia Type 2 Diabetes CAD Sleep Apnea Other consequences: Gall bladder disease Certain cancers Death |
|
why causes obesity
#kcal that = 1 lb of fat |
Imbalance in calories ingested versus calories burned
3500 kcal = 1 lb fat |
|
discrepancy between reported and actual energy intake and expenditure: significant difference
|
most people think they are eating way less calories than they are actually eating, and reporting higher amts of energy expenditure
|
|
greatest areas for prevention and treatment actions (2)
|
Behavior and environment play a large role causing people to be overweight and obese.
|
|
Process of metabolism is mediated by ______ and _____ influenced by _______
|
endocrine and neural pathways and influenced by genetics
|
|
In the setting of excess caloric intake and deficient caloric expenditure what happens? (3)
|
excess fat is deposited
over time this = weight gain Even small changes can have large effects |
|
5 things that regulate appetite
name 2 hormones |
psych factors involved (emotions, reward, learning...)
cultural factors hormones/peptides in gut (grelin- "grr" and leptin which tells you when you're full) neural afferents metabolites |
|
4 things that affect caloric expenditure
|
Resting or basic metabolic rate (~70% of daily energy expenditure)
Energy cost of metabolizing and storing food Thermic effect of exercise (only 10-20%) Adaptive thermogenesis aka regulation of heat (varies in response to chronic caloric intake) |
|
adipocytes are also what?
|
also an endocrine cell that releases numerous molecules in a regulated fashion
|
|
4 hormones/stuff that adipocytes excrete
|
leptin
adiponectin resistin cytokines |
|
leptin- in fasted vs. fed state
in obesity (say what it does- 2 things) |
fasted state = decreased in leptin, increase in grelin- stimulates appetite and decreases energy expenditure
fed state = increased leptin = decrease apptetite and increase energy expenditure different in obesity- leptin resistance so it doesn't decrease appetite and increase energy expenditure |
|
4 roles of leptin
|
glucose and lipid metabolism
hunter/satiety thermogenesis/autonomic system neuroendocrine fxn |
|
Body weight is the result of (6)
|
genes, metabolism, behavior, environment, culture, and socioeconomic status
|
|
obesity and genetics- what makes it hard to determine role of genes?
|
Obesity is commonly seen in families so it's difficult to distinguish role of genes vs. environment
|
|
genetics affects both...(2)
|
appear to affect both appetite and energy expenditure
|
|
environmental causes of obesity (3)
|
cultural/societal things like:
availability of food types of activities economic drivers- marketing/profits (cheap, fast food makes more profits) |
|
in addition to environment and genes, 2 things that affect obesity
|
medications
diseases |
|
diseases that cause obesity (6)
|
Cushing disease, growth hormone deficiency, hypothyroidism, insulinoma (insulin causes glucose to be taken up into cells and stored as fat), leptin deficiency, and various psychiatric disorders,
|
|
5 categories of meds that cause obesity
|
atypical antipsychotics
anticonvulsants antidepressants conventional antipsychotics (haloperidol) hormones |
|
4 anticonvulsants that cause fattiness
|
carbamazepine, gabapentin, pregabalin, and valproic acid
|
|
2 antidepressants that cause obesity
|
mirtazapine and tricyclic antidepressants
|
|
4 atypical antipsychotics that cause obesity
|
clozapine, olanzapine, quetiepine, and risperidone
|
|
3 hormone meds that cause obesity
|
corticosteroids, insulin, and medroxyprogesterone
|
|
who should be advised on weight? (4)
|
basically anyone who meets overweight
BMI 25-29.9 OR waist circumference >40”male/>35”female AND >2 risk factors OR BMI>30 but actually...everyone should be...wtf |
|
initial eval of someone's obesity (questions to ask) related to the patient's past/why he's fat (6)
|
History of weight gain
Maximum body weight Any meds causing/worsening weight gain Previous approaches to quit Patterns of food intake (including binge eating) Physical activity |
|
evaluation of patient- questions to ask/things to note regarding patient's current status and ability to succeed at weight loss (5)
|
Current BMI & waist circumference
Presence of comorbidities Assess the patient’s readiness to lose weight Identify barriers to success Identify reasonable approaches to weight loss for individual patient |
|
risk factors for major comorbidities (6)
|
Cardiovascular disease
Type 2 Diabetes (includes pre-diabetes: Impaired fasting glucose (100-125 mg/dL) and Impaired glucose tolerance (post-prandial 140-200 mg/dL) HTN Hyperlipidemia Obstructive Sleep Apnea Increased waist circumference |
|
3 weight loss goals
|
Prevent further weight gain
Reduce body weight Maintain a lower body weight over the long term |
|
how much weight to lose? (per week? per 6 months? maintain for how long?)
overall, in terms of patterns of weight loss what is better? |
Recommend 10% weight loss at 6 months
1-2 pound loss per week Maintain for 6-12 months and then set goals for further weight loss Better to lose a little weight and maintain the lower weight than lose a lot only to regain it over time |
|
gradual weight loss and maintenance is associated with... (4)
|
Associated with decrease in obesity- associated risk factors (BP, lipids, sugars, waist circumference)
|
|
lifestyle approaches to weight loss/maintenance (3)
difficulty? |
Dietary approaches
Physical activity Behavior modification MOST DIFFICULT TO ADHERE TO |
|
which diet to choose for weight loss?
diets and rapid weight loss- what do studies suggest about these? do people normally maintain this weight loss? |
NONE IT'S THE CALORIES THAT COUNT
Some diets may result in more rapid weight loss but most studies suggest that weight loss is similar at one year with some studies showing different results Most people will lose weight on a diet at 6 months; however, most will regain weight by 12 to 24 months. |
|
well balanced diet shit
|
---
|
|
daily caloric requirements- what is it made up of? name of formula (don't have to calculate)
if obese how do you use this formula? |
Basal Metabolic Rate plus Activity Factor (harris benedict formula)
if obese- will overestimate, so may help to use IBW |
|
For healthy weight loss, what caloric deficit do you need?
women daily kcals men daily kcals never go below... how you would go about reaching these levels of kcals |
Need a caloric deficit of ~500 kcal/day
Women: 1,000-1,200 kcal/day Men: 1,200-1,600 kcal/day Never <800 kcal/day make sure to "titrate" to these lvls depending on person's current intake |
|
physical activity properties (2)
|
Very important to overall health/maintenance of weight and should be part of weight loss plan
Activity alone is often insufficient to lose weight |
|
how much physical activity (time, frequency per week)
good way to reach goal |
>30 minutes for >5 days/week
May need to set small goals and work up to this target |
|
4 benefits of physical activity beyond weight loss
|
Decrease in blood pressure
Decrease in triglycerides & LDL Increase in HDL Decrease in mortality |
|
5 behavioral modifications to make
|
Goal setting
Self-monitoring: diet diary Stimulus control Cognitive restructuring Prevention of relapse |
|
when does weight loss pharmacotherapy come into play? (2)
|
If weight loss goals are not met after 6 months of lifestyle modification, then pharmacotherapy for weight loss may be considered as an adjunct
also if they are at certain BMIs (obese, >=30) weight loss meds are indicated as adjunct therapy |
|
eligibility criteria for weight loss meds (2 tiers)
|
BMI 27-29.9 plus 2 comorbid conditions &/or risk factors
BMI>30 with or without comorbid conditions &/or risk factors |
|
biggest failure in the past with weight loss drugs
major issues (2) with this drug |
in the 90s, with phen-fen
pulmonary hypertension, valvulopathies in almost a third of pts |
|
4 drug categories/types currently out on market for WL
|
Sympathomimetic Amines
Lipase inhibitor (Orlistat) Belviq (lorcaserin) Qsymia (phentermine & topiramate) |
|
4 sympathomimetic amines for WL
|
Phentermine, Diethylpropion, Benzphetamine, Phendimetrazine
|
|
sympathomimetic amines- duration of use
|
Indicated for short-term (up to 12 weeks) treatment (often used >12 weeks)
|
|
efficacy of sympathomimetic amines
tolerance? permanence of effect? side effects prominent? controlled? |
~3 kg placebo adjusted weight loss
Tolerance to effects develops over time Weight is typically regained after therapy Associated with clinically significant side effects All are controlled substances |
|
indication of sympatho amines (duration of treatment and age)
|
adults and adolescents>16 y.o.a. for short-term (8-12 weeks) treatment of obesity
|
|
MoA of sympathomimetic amines (2)
|
Increase NE transmission, decrease NE reuptake
Decrease appetite by stimulating satiety centers in the brain |
|
when to dose sympatho amines
(don't have to know actual dosing? he said for reference) |
Avoid dosing later in the day to minimize risk for insomnia
|
|
Phentermine dosing
|
15-37.5 mg/day
|
|
AE of sympatho amines (6)
|
Dry mouth
Constipation Elevated blood pressure Elevated heart rate Insomnia Nervousness |
|
PPH (primary pulmonary hypertension) and appetite suppressants
|
PPH incidence in appetite suppressant use is slightly higher but consider that obesity itself increases risk. therefore the absolute risk of PPH is pretty small when using these drugs.
|
|
8 conditions to avoid sympatho amines
|
Cardiovascular disease (PPH, HF) hypertension, valvulopathy
Anxiety/agitated states History of drug abuse, addictive tendency Hyperthyroidism glaucoma Pregnancy, nursing or lactating women |
|
drug interactions with sympatho amines (2)
|
MAOI’s (at least 14 days between use must be observed)-
SSRI’s |
|
when to stop sympatho amines (2)
long term success? |
Stop if intolerable side effects
Stop if <4 pound weight loss at 4 weeks=unlikely to respond Evidence for long-term success is limited |
|
orlistat indication (include age)
|
Weight loss and maintenance in adults and adolescents >12 yoa
|
|
MoA/absorption of orlistat
|
GI Lipase inhibitor-decreases fat absorption
Little to no systemic absorption of drug |
|
orlistat- when to dose
efficacy depends on what? |
only works if taken within an hour of food
if pt wasn't eating high fats then this won't help |
|
orlistat in clinical trials- efficacy
long term use |
patients on orlistat achieved 2-4 kg weight loss in1 year- most trials favored treatment with orlistat
little better data for long term use- 2 year trial of pt switching from orlistat to placebo, staying on orlistat, etc. showed weight maintenance |
|
orlistat effect on LDL and visceral fat
|
LDL cholesterol mean percent change higher in orlistat users...duh.
also significant decrease in abdominal (visceral) fat |
|
2 forms of orlistat and dosing
cost |
Xenical 120 mg TID with meals
Alli 60 mg TID with meals $$$$$ |
|
6 AE of orlistat
|
fatty/oily stool
oily spotting fecal urgency fecal incontinence increased pooping flatulance |
|
orlistat AEs over time...
|
AE decreases over time- may be because pt stop eating high fats
|
|
avoid using orlistat in pt with...(3)
|
Cholestasis
Chronic malabsorption syndrome Very high fat meal-increase GI toxicity |
|
orlistat and vitamin/drug absorption- which ones does it affect? (5 vitamins, 1 drug)
how to remedy this? (2) |
Reduced absorption of Vitamins ADEK, beta-carotene- ie the fatty ones-and cyclosporine (interferes with absorption): separate other drugs by 2 hours & take multivitamin
|
|
Strict FDA Approval Criteria for Treatment of Obesity (3)
|
Induce statistically significant placebo-adjusted weight loss of >5% at 1 year OR
>35% of patients should achieve >5% weight loss (which must be at least twice that induced by placebo) also requires that the medication show evidence of improvement in metabolic biomarkers, including blood pressure, lipids, and glycemia. |
|
lorcaserin indication- when/how to use
patient criteria (BMI, 2 tiers) |
adjunct to diet & exercise for chronic weight management in adults with BMI >30 or >27 with >1 comorbid condition (HTN, HL, T2DM) what about sleep apnea and shiz?
|
|
lorcaserin MoA
|
5-HT2C receptor agonist-decreases appetite and increases satiety
|
|
dosing of lorcaserin
when do you d/c |
10 mg twice daily; stop at week 12 if 5% weight loss has not been achieved
|
|
common AE of lorcaserin (5)
|
Nausea, dizziness, headache, fatigue, nasopharyngitis
|
|
serious AE of lorcaserin (4)
|
hypoglycemia (T2DM pt incidence is ~29%- idk serotonin regulates insulin), serotonin syndrome, heart valve disorder (2.4%), suicidal thoughts (0.6%)
|
|
lorcaserin DDIs (2 categories of drugs- 2 in the first one, 3 in the second)
|
Drugs with serotonin activity: SSRI’s, SNRI’s, TCA’s
Drugs metabolized by CYP2D6: metoprolol, codeine, tamoxifen |
|
CI for lorcaserin
caution in...(4) |
Avoid in pregnancy
Caution in CKD, heart block, heart failure, depression |
|
trials for lorcaserin- duration, pt population,# of trials
avg weight loss % that achieved at least 5% weight loss weight maintained if stop drug? |
3 R,DB,PC trials 1-2 years in duration (2 trials without DM, 1 with DM)
avg weight loss was 3-3.7% 50% pt lost at least 5% in study with no T2Dm...kind of shit pt who stop drug regain weight |
|
locarserin effect on LDL/BP/glucose
|
small but statistically significant difference in LDL/BP/glucose
...not sure if clinically significant |
|
benefits of using combo therapy (2)
|
Lower doses of multiple agents may decrease risk for toxicity from higher doses of single agents
Some drugs in combo have been used as single agents so may have a track record of safety or least more well known than an entirely new drug |
|
topiramate MoA for WL?
efficacy |
~5 to 7% placebo adjusted weight loss
MoA unknown but controls satiety |
|
Qsymia (formerly QNEXA) what is it
|
Topiramate and phentermine
|
|
WL treatment algorithm...
|
---
|
|
Qsymia indication- when to use?
criteria for use in adults (2) |
adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with BMI >30 or >27 and >1 comorbidity (HTN, T2DM, HL)
|
|
Qsymia MoA (2)
|
decreased appetite and increased satiety (exact MOA is unknown)
|
|
dosing of Qsymia- initial dosing (have to titrate due to topamax)
maintenance dosing max dose |
Initial: phentermine 3.75 mg/topiramate 23 mg once daily in the morning X 14 days
Maintenance: P-7.5 mg/T-46 mg once daily Maximum: P-15 mg/T-92 mg once daily |
|
6 AE of Qsymia
|
Paresthesia, dizziness, altered taste (these are topamax)
insomnia, constipation, dry mouth (phentermine) |
|
Qsymia 6 DDIs and why
|
MAOI’s: avoid within 14 days-HTN crisis
Oral contraceptives CNS depressants including alcohol Non-K+ sparing diuretics: risk of hypokalemia Antiepileptic drugs Carbonic anhydrase inhibitors: increased metabolic acidosis |
|
CI Qsymia (4)
|
Avoid in pregnancy, glaucoma, hyperthyroidism, within 14 days of MAIOI
|
|
Qsymia can cause an increase in...(5)
|
Increase in heart rate, suicidal behavior, mood & sleep disorder, metabolic acidosis,
|
|
Qsymia precautions (4)
|
caution in CKD-increased SCr & max dose
risk of hypoglycemia with T2DM on meds hypotension with anti-HTN meds?? wtf potential seizures with abrupt withdrawal (topamax) |
|
Qsymia- # of trials
efficacy in trials % of pt that lost > 5% effects on comorbidities |
Two Phase III trials
>5% placebo adjusted weight loss ~45-70% of patients lost >5% still shitty Improvements in comorbidities |
|
using the highest dose of Qsymia was associated with what (heart issue)
|
Highest dose=increase heart rate of 1.5 bpm
|
|
Contrave (in approval process)- what is it
|
Buproprion (NDRI) and Naltrexone (opioid antagonist)
|
|
Buproprion - what's it do for pt?
efficacy of WL |
decrease appetite and food cravings: ~2.8 kg at 52 weeks
|
|
Contrave at 48 weeks- how much WL?
|
~10 kg wt loss
|
|
Contrave # of clinical trials
|
4 phase III trials=fairly good results
|
|
last line for WL
|
surgery!
|
|
4 types of WL surgery
which is most common goal of all of these surgeries |
Vertical banded gastroplasty (VBG)
Roux-en-Y gastric bypass (RYGB)**most common- bypasses the stomach decreasing absorption, and metabolic/hormonal changes Gastric banding- band the stomach Biliopancreatic diversion- Part of the stomach is resected, creating a smaller stomach (however the patient can eat a free diet as there is no restrictive component). The distal part of the small intestine is then connected to the pouch, bypassing the duodenum and jejunum. all restrict capacity in stomach and decrease absorption |
|
efficacy of WL surgery
|
Currently most effective method
~40-70% weight loss |
|
WL surgery effect on comorbidities (3)
|
Diabetes: 89% resolved
HTN: 66% resolved OSA (obstructive sleep apnea): 40% resolved |
|
complications of WL surgery (4)
|
Nutritional deficiencies, obstruction, infection, death
|
|
pt on WL surgery- really important to advice them on what? (2)
|
Advise patient on multivitamin and vitamin D supplements
|
|
CAM (complementary/alternative medications) for WL- (3) good bad?
|
CAM are not regulated like meds
Not tested for safety or efficacy Some may be dangerous e.g. ephedra was a stimulant similar to amphetamine that fucked people up |
|
7 CAMS and their MoA (for some)
|
Bitter orange- noradrenergic
calcium pyruvate chromium chitosan- cationic polypeptide that blocks fat absorption garcinia guarana- noradrenergic (Caffeine) hoodia tea extracts- noradrenergic (caffeine) |
|
stupid summary slide
|
--
|